- Home
- FOF vs XFOR Comparison
FOF vs XFOR Comparison
Compare FOF & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOF | XFOR |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.1M | 323.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOF | XFOR |
|---|---|---|
| Price | $13.79 | $3.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 58.7K | ★ 403.9K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,979,000.00 |
| Revenue This Year | N/A | $1,266.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $9.59 | $1.35 |
| 52 Week High | $11.75 | $24.43 |
Technical Indicators
Market Signals| Indicator | FOF | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 72.59 | 45.99 |
| Support Level | $13.48 | $3.57 |
| Resistance Level | $13.67 | $3.89 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 93.44 | 25.00 |
Price Performance
Historical ComparisonAbout FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.